enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 29,800 shares, a decline of 82.6% from the July 15th total of 171,700 shares. Based on an average trading volume of 123,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ENGN. Guggenheim began coverage on shares of enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 price target for the company. Wells Fargo & Company initiated coverage on shares of enGene in a report on Monday, April 22nd. They issued an “overweight” rating and a $30.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, enGene has a consensus rating of “Buy” and a consensus target price of $34.40.

Hedge Funds Weigh In On enGene

Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new position in shares of enGene in the first quarter worth $17,095,000. Altitude Crest Partners Inc. purchased a new position in shares of enGene in the first quarter worth $2,039,000. Omega Fund Management LLC bought a new stake in enGene in the fourth quarter worth $10,441,000. BVF Inc. IL bought a new stake in enGene in the fourth quarter worth $20,777,000. Finally, Vivo Capital LLC bought a new stake in enGene in the fourth quarter worth $6,264,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Stock Down 7.4 %

NASDAQ:ENGN traded down $0.49 during trading hours on Tuesday, hitting $6.11. 217,308 shares of the stock traded hands, compared to its average volume of 87,541. enGene has a 1 year low of $6.00 and a 1 year high of $43.00. The company has a market cap of $269.85 million, a price-to-earnings ratio of -4.05 and a beta of -0.63. The stock has a 50 day moving average price of $8.61 and a 200 day moving average price of $12.27.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Friday, June 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.14). Equities analysts forecast that enGene will post -1.33 earnings per share for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.